<
Von Version < 7.1 >
bearbeitet von Thomas Brinkmeier
am 2020/06/04 01:06
Auf Version < 20.1 >
bearbeitet von Thomas Brinkmeier
am 2024/09/07 22:03
>
Änderungskommentar: Es gibt keinen Kommentar für diese Version

Zusammenfassung

Details

Wikiderm.EntryClass[0]
Eintrag
... ... @@ -59,17 +59,62 @@
59 59  (% class="Bullet" %)-(%%) Pyoderma gangraenosum
60 60  
61 61  (% class="Eintrag-2" %)
62 -(% class="Feature" %)TF:(%%) Infekte
62 +(% class="Feature" %)TF:(%%) (% class="Bullet" %)-(%%) Infekte
63 63  
64 64  (% class="Ebene-2" %)
65 65  (% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV
66 66  
67 +(% class="Ebene-1" %)
68 +(% class="Bullet" %)-(%%) Dupilumab
69 +
70 +(% class="Ebene-2" %)
71 +(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2023 Nov 27. [[http:~~/~~/doi.org/10.1111/ajd.14190>>url:http://doi.org/10.1111/ajd.14190]]
72 +
67 67  (% class="Eintrag-2" %)
68 -(% class="Feature" %)DD:(%%) (% class="Abbreviation" %)AGEP(%%), Dermatitis herpetiformis, eosinophile pustulöse Follikulitis Ofuji, Impetigo contagiosa, Pemphigus foliaceus, Psoriasis pustulosa
74 +(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) AGEP
69 69  
76 +(% class="Ebene-1" %)
77 +(% class="Bullet" %)-(%%) Dermatitis herpetiformis
78 +
79 +(% class="Ebene-1" %)
80 +(% class="Bullet" %)-(%%) eosinophile pustulöse Follikulitis Ofuji
81 +
82 +(% class="Ebene-1" %)
83 +(% class="Bullet" %)-(%%) Impetigo contagiosa
84 +
85 +(% class="Ebene-1" %)
86 +(% class="Bullet" %)-(%%) Pemphigus foliaceus
87 +
88 +(% class="Ebene-1" %)
89 +(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
90 +
91 +(% class="Ebene-2" %)
92 +(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
93 +
94 +(% class="Ebene-2" %)
95 +(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
96 +
97 +(% class="Ebene-1" %)
98 +(% class="Bullet" %)-(%%) Tinea incognito
99 +
100 +(% class="Ebene-2" %)
101 +(% class="Feature" %)Lit:(%%) [[Kalkan, G., Demirseren, D. D, Güney, C. A, & Aktaş, A. (2020). A case of tinea incognito mimicking subcorneal pustular dermatosis. Dermatology Online Journal, 26(2)>>url:https://escholarship.org/uc/item/46g9x55w]]
102 +
70 70  (% class="Eintrag-2" %)
71 -(% class="Feature" %)Lit:(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}}
104 +(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}}
72 72  
106 +(% class="Ebene-1" %)
107 +(% class="Bullet" %)-(%%) Open Access Maced J Med Sci. 2020 Jun 05; 8(T1):12-15. [[https:~~/~~/doi.org/10.3889/oamjms.2020.4870>>url:https://doi.org/10.3889/oamjms.2020.4870]]
108 +
109 +(% class="Ebene-1" %)
110 +(% class="Bullet" %)-(%%) International Journal of Women's Dermatology, Volume 6, Issue 3, 2020, Pages 131-136, ISSN 2352-6475, [[https:~~/~~/doi.org/10.1016/j.ijwd.2020.02.003>>url:https://doi.org/10.1016/j.ijwd.2020.02.003]]
111 +
112 +(% class="Ebene-1" %)
113 +(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]]
114 +
115 +(% class="Ebene-1" %)
116 +(% class="Bullet" %)-(%%) JAAD Case Rep. 2022 Jan 21;21:185-188. [[http:~~/~~/doi.org/10.1016/j.jdcr.2021.04.039>>url:http://doi.org/10.1016/j.jdcr.2021.04.039]]
117 +
73 73  (% class="Eintrag-2" %)
74 74  (% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal
75 75  
... ... @@ -77,6 +77,12 @@
77 77  (% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**)
78 78  
79 79  (% class="Ebene-2" %)
125 +(% class="Bullet" %)-(%%) Mometasonfuroat
126 +
127 +(% class="Ebene-3" %)
128 +(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]]
129 +
130 +(% class="Ebene-2" %)
80 80  (% class="Bullet" %)-(%%) Tacalcitol
81 81  
82 82  (% class="Ebene-3" %)
... ... @@ -83,7 +83,7 @@
83 83  (% class="Feature" %)Lit:(%%) J Dermatol 2000; 27: 669-72
84 84  
85 85  (% class="Ebene-3" %)
86 -(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
137 +(% class="Feature" %)PT:(%%) CR
87 87  
88 88  (% class="Ebene-3" %)
89 89  (% class="Feature" %)Altn:(%%) Maxacalcitol
... ... @@ -92,7 +92,7 @@
92 92  (% class="Feature" %)Lit:(%%) Clin Exp Dermatol. 2015 May 19. [[http:~~/~~/doi.org/10.1111/ced.12680>>url:http://doi.org/10.1111/ced.12680]]
93 93  
94 94  (% class="Ebene-5" %)
95 -(% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%)
146 +(% class="Feature" %)Lit:(%%) CR
96 96  
97 97  (% class="Ebene-2" %)
98 98  (% class="Bullet" %)-(%%) Dapson Gel
... ... @@ -107,7 +107,7 @@
107 107  (% class="Bullet" %)-(%%) Dapson
108 108  
109 109  (% class="Ebene-3" %)
110 -(% class="Feature" %)Bed:(%%) (% class="Abbreviation" %)GS(%%)
161 +(% class="Feature" %)Bed:(%%) GS
111 111  
112 112  (% class="Ebene-3" %)
113 113  (% class="Feature" %)Dos:(%%) 100-150 mg/Tag
... ... @@ -146,8 +146,11 @@
146 146  (% class="Bullet" %)-(%%) Apremilast
147 147  
148 148  (% class="Ebene-3" %)
149 -(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
200 +(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
150 150  
202 +(% class="Ebene-3" %)
203 +(% class="Bullet" %)-(%%) Australas J Dermatol. 2023 Aug;64(3):e310-e312. [[http:~~/~~/doi.org/10.1111/ajd.14073>>url:http://doi.org/10.1111/ajd.14073]]
204 +
151 151  (% class="Ebene-2" %)
152 152  (% class="Bullet" %)-(%%) Anti-TNF-alpha
153 153  
... ... @@ -155,14 +155,8 @@
155 155  (% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
156 156  
157 157  (% class="Ebene-4" %)
158 -(% class="Feature" %)Phar:(%%) Remicade^^®^^
212 +(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
159 159  
160 -(% class="Ebene-4" %)
161 -(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
162 -
163 -(% class="Ebene-4" %)
164 -(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
165 -
166 166  (% class="Ebene-3" %)
167 167  (% class="Bullet" %)-(%%) Adalimumab
168 168  
... ... @@ -171,3 +171,10 @@
171 171  
172 172  (% class="Ebene-5" %)
173 173  (% class="Feature" %)PT:(%%) CR
222 +
223 +(% class="Ebene-2" %)
224 +(% class="Bullet" %)-(%%) Guselkumab
225 +
226 +(% class="Ebene-3" %)
227 +(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]]
228 +

Artikelinhalt

©WIKIDERM GmbH • KontaktFAQImpressumNutzungsbedingungenDatenschutzerklärungFacebook